Navigation Links
New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event
Date:5/24/2012

SAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies.  Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capitalists, and industry leaders.

This award represents another important achievement for Electrochemical Oxygen Concepts (EO2), the maker of the TransCU O2®.  The company has also recently received recognition by the Department of Veterans Affairs.  EO2 CEO Michael Wells says he and his team are honored by the accolades.

"Patients suffering from chronic wounds and their physicians have long been in need of a better therapy to treat their condition," said Wells. "This award from the Texas Life Science Venture Forum further confirms that TransCU O2® is a ground breaking therapy with the ability to improve the health and lives of patients who suffer with difficult-to heal wounds."

The TransCU O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-dose pure oxygen to treat a variety of wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds but current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCU O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring and automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

The Texas Life Science Venture Forum is a joint effort between the Rice Alliance of Technology and Entrepreneurship, BioHouston, and the Texas Healthcare and BioScience Institute and part of the three-day Texas Life Science Conference.  The conference is the most comprehensive showcase of cutting-edge research and innovative entrepreneurs in the state.  Hundreds of investors, entrepreneurs, successful business people and industry leaders attended to learn about, evaluate and network with the presenting companies.

About Electrochemical Oxygen Concepts (EO2™ Concepts):
EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  TransCU O2® is a registered trade mark of Electrochemical Oxygen Concepts.  For more information, please visit www.eo2concepts.com.  

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/26/2016)... Indiana (PRWEB) , ... May 26, 2016 , ... ... provider of healthcare supply chain solutions, today announced the organization has earned its ... meets international standards and is compliant with all rules and policies associated with ...
(Date:5/26/2016)... Cypress, Texas (PRWEB) , ... May 26, 2016 , ... ... on Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of ... a non-profit that restores, empowers, and renews hope for wounded service members and their ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age ... speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the ... a member of the Institute for Functional Medicine. , He also heads up FITTLab, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the ... bunionette) treatment was more than humbled by customer demand over the Mother’s Day Weekend ... mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes ...
(Date:5/26/2016)... ... 26, 2016 , ... A health conscious snack that doesn't sacrifice taste? It's ... ignited an undeniable buzz in the protein product community by offering an alternative to ... doughnuts are packed with 11 grams of protein and made from a healthy blend ...
Breaking Medicine News(10 mins):